Driven by improved performance of the formulations division, especially the demand for metformin, Granules India Ltd (GIL) logged a 63 per cent growth in net profit at Rs 3 crore (Rs 2 crore) for the first quarter ended June 30, 2011.
The formulations contributed Rs 37 crore in a turnover of Rs 119 crore for the quarter (Rs 109 crore).
Expansion complete
Granules, an integrated formulations manufacturer, expects growth in Q2 and Q3 riding on its ibuprofen, a press release said.
In addition, the company completed the expansion of a new PFI (pharmaceutical formulation intermediates) module, which will increase capacity by 1,200 tonnes annually.
The company is also on track to finish an 8,000 tonnes annually PFI module and a 12 billion dosage formulation module by the end of the fiscal year.
The basic EPS was Rs 1.56 for the quarter (Rs 0.96).
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.